Cell therapy manufacturing is one of the most exciting and demanding areas in life sciences. It sits at the intersection of advanced biology, personalised medicine, complex supply chains and highly controlled GMP operations. For QA and QC teams, the challenge is clear: how do we scale cell therapy manufacturing without losing the quality control
For quality assurance professionals, sustainability can sometimes feel like a difficult conversation. On one side, organisations are under growing pressure to reduce waste, lower energy consumption, cut carbon emissions and improve environmental performance. On the other hand, GMP environments are built on control, consistency, validation, documentation and patient safety. So, can sustainability and GMP
Temperature-sensitive products leave very little room for complacency. Whether the product is a vaccine, biologic, cell therapy, diagnostic reagent, clinical trial material or pharmaceutical product requiring controlled storage, the cold chain is only as strong as its weakest handover. For QA teams, this means quality oversight can no longer stop at the warehouse door.
In pharmaceutical manufacturing, batch release is one of the most critical stages in the product lifecycle. Delays at this stage can create significant operational, financial, and supply chain challenges, impacting everything from inventory levels and production schedules to patient access and regulatory compliance. For modern Quality Assurance (QA) teams, reducing batch release delays has
Regulatory inspections remain one of the most important aspects of pharmaceutical quality assurance. As the pharmaceutical industry continues to evolve through digital transformation, global supply chain complexity, and increasing regulatory expectations, organisations must ensure they are consistently inspection-ready. Both the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA)
